Definium Therapeutics, Inc.
DFTXHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeDefinium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. At a $2.56B market cap, Definium Therapeutics, Inc. ranks as a mid-cap company within healthcare. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Market Cap
$2.56B
Beta
2.38
P/E (TTM)
—
P/E (Fwd)
-14.85
EPS (TTM)
$-2.50
EPS (Fwd)
$-1.58
ROE
-94.7%
ROA
-35.7%
Cash
$373.4M
Total Debt
$40.8M
Free CF
-$45.6M
52W Change
223.4%
Annual Financials
Cash vs Debt
Definium Therapeutics, Inc. holds $373.4M in cash against $40.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$45.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -94.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.38 means DFTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, DFTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Definium Therapeutics, Inc. and its sector.